Experimental trials in amyotrophic lateral sclerosis: A review of recently completed, ongoing and planned trials using existing and novel drugs

Expert Opinion on Investigational Drugs

Volumn 23, Issue 11, 2014, Pages 1541-1551

  Goyal, Namita A ^a,b   Mozaffar, Tahseen ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyotrophic lateral sclerosis; Clinical trials; Motor neuron disease; Stem cell therapy

Indexed keywords

AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; ANTISENSE OLIGONUCLEOTIDE; ARIMOCLOMOL; CEFTRIAXONE; COPPER ZINC SUPEROXIDE DISMUTASE; DEXPRAMIPEXOLE; FINGOLIMOD; LITHIUM; MEXILETINE; NP 001; OZANEZUMAB; PROTEIN NOGO A; RASAGILINE; TALAMPANEL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; NEUROPROTECTIVE AGENT; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ASTROCYTE; ASTROCYTE PRECURSOR CELL; DRUG EFFICACY; DRUG SAFETY; HEMATOPOIETIC STEM CELL; HUMAN; MESENCHYMAL STEM CELL; MULTICENTER STUDY (TOPIC); NERVE FIBER GROWTH; NEURAL STEM CELL; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; ANIMAL; DRUG DESIGN; METABOLISM; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT SELECTION; PROCEDURES;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEUROPROTECTIVE AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; RILUZOLE; STEM CELL TRANSPLANTATION;

EID: 84911394418     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.933807     Document Type: Review

References (99)

1. Chuang DM, Chen RW, Chalecka-Franaszek E, et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002;4:129-36
2. Rametti A, Esclaire F, Yardin C, et al. Lithium down-regulates tau in cultured cortical neurons: A possible mechanism of neuroprotection. Neurosci Lett 2008;434:93-8
3. Hashimoto R, Takei N, Shimazu K, et al. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: An essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 2002;43:1173-9
4. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008;105:2052-7
5. Fornai F, Longone P, Ferrucci M, et al. Autophagy and amyotrophic lateral sclerosis: The multiple roles of lithium. Autophagy 2008;4:527-30
6. Sarkar S, Floto R, Berger Z, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 2005;170:1101-11
7. Aggarwal S, Zinman L, Simpson E, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: A randomised, double-blind, placebocontrolled trial. Lancet Neurol 2010;9:481-8
8. Chio A, Borghero G, Calvo A, et al. Lithium carbonate in amyotrophic lateral sclerosis: Lack of efficacy in a dosefinding trial. Neurology 2010;75:619-25
9. Miller R, Moore D, Forshew D, et al. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: Examining a more efficient trial design. Neurology 2011;77:973-9
10. Wicks P, Vaughan T, Massagli M, Heywood J. Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm. Nat Biotechnol 2011;29:411-14
11. Verstraete E, Veldink J, Huisman M, et al. Lithium lacks effect on survival in amyotrophic lateral sclerosis: A phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry 2012;83:557-64
12. Group UK-LS. Morrison K, Dhariwal S, Hornabrook R, et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): A phase 3 multicentre, randomised, double-blind, placebocontrolled trial. Lancet Neurol 2013;12:339-45
13. Hirata A, Nakamura R, Kwak S, et al. AMPA receptor-mediated slow neuronal death in the rat spinal cord induced by long-Term blockade of glutamate transporters with THA. Brain Res 1997;771:37-44
14. Legay V, Deleage C, Beaulieux F, et al. Impaired glutamate uptake and EAAT2 downregulation in an enterovirus chronically infected human glial cell line. Eur J Neurosci 2003;17:1820-8
15. Rothstein J, Patel S, Regan M, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433:73-7
16. Rothstein J, Van Kammen M, Levey A, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84
17. Maragakis N, Dykes-Hoberg M, Rothstein J. Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann Neurol 2004;55:469-77
18. Van Den Bosch L, Robberecht W. Crosstalk between astrocytes and motor neurons: What is the message?. Exp Neurol 2008;211:1-6
19. Canton T, Beohme G, Boireau A, et al. RPR 119990, a novel alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: Synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2001;299:314-22
20. Van Damme P, Leyssen M, Callewaert G, et al. The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci Lett 2003;343:81-4
21. Chappell A, Sander J, Brodie M, et al. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 2002;58:1680-2
22. Greene I, Lee E-Y, Prow N, et al. Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infection. Proc Natl Acad Sci USA 2008;105:3575-80
23. Pascuzzi R, Shefner J, Chappell A, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11:266-71
24. Nizzardo M, Nardini M, Ronchi D, et al. Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms. Exp Neurol 2011;229:214-25
25. Miller B, Dorner J, Shou M, et al. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntingtons disease phenotype in the R6/2 mouse. Neuroscience 2008;153:329-37
26. Melzer N, Meuth S, Torres-Salazar D, et al. A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis. PLoS One 2008;3:e3149
27. Theone-Reineke C, Neumann C, Namsolleck P, et al. The beta-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke. J Hypertens 2008;26:2426-35
28. Rothstein J, Kuncl R. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 1995;65:643-51
29. Carreer R, Deby-Dupont G, Deby C, et al. Oxidant-scavenging activities of beta-lactam agents. Eur J Clin Microbiol Infect Dis 1998;17:43-6
30. Berry J, Shefner J, Conwit R, et al. Design and initial results of a multiphase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One 2013;8:e61177
31. Miller RG, Block G, Gopalakrishnam V, McGrath M; Grp NPPIS. Phase II Trial of NP001 in ALS. Ann Neurol 2013;74:S95-5
32. Neuraltus. Neuraltus Pharmaceuticals NP001 Phase 2 Results Highlighted at the 24th International Symposium on ALS/MND [online]. Available from: Http://www.neuraltus.com/pages/ news-rel12-09-13.html [Accessed 6 June 2014]
33. Renton A, Chio A, Traynor B. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014;17:17-23
34. Rothstein J. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009;65(Suppl 1):9
35. Miller T, Smith R, Kordasiewicz H, Kaspar B. Gene-Targeted therapies for the central nervous system. Arch Neurol 2008;65:447-51
36. Bennett C, Swayze E. RNA targeting therapeutics: Molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010;50:259-93
37. Smith R, Miller T, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006;116:2290-6
38. Miller T, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study. Lancet Neurol 2013;12:435-42
39. Alavian K, Dworetzky S, Bonanni L, et al. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res 2012;1446:1-11
40. Danzeisen R, Schwalenstoecker B, Gillardon F, et al. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-Amino-4, 5, 6, 7-Tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther 2006;316:189-99
41. Bozik M, Mather J, Kramer W, et al. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. J Clin Pharmacol 2011;51:1177-85
42. Cudkowicz M, Bozik M, Ingersoll E, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 2011;17:1652-6
43. Cudkowicz M, van den Berg L, Shefner J, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): A randomised, double-blind, phase 3 trial. Lancet Neurol 2013;12:1059-67
44. Berry J, Miller R, Moore D, et al. The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:162-8
45. Hargitai J, Lewis H, Boros I, et al. Bimoclomol, a heat shock protein coinducer, acts by the prolonged activation of heat shock factor-1. Biochem Biophys Res Commun 2003;307:689-95
46. Kalmar B, Burnstock G, Vrbova G, et al. Upregulation of heat shock proteins rescues motoneurones from axotomyinduced cell death in neonatal rats. Exp Neurol 2002;176:87-97
47. Kalmar B, Lu CH, Greensmith L. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol. Pharmacol Ther 2014;141:40-54
48. Kieran D, Kalmar B, Dick J, et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10:402-5
49. Cudkowicz M, Shefner J, Simpson E, et al. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve 2008;38:837-44
50. Lee K, Yoon D, Chung MA, et al. Neuroprotective effects of mexiletine on motor evoked potentials in demyelinated rat spinal cords. Neurosci Res 2010;67:59-64
51. Ates O, Cayli S, Gurses I, et al. Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury. J Clin Neurosci 2007;14:658-65
52. Ates O, Cayli S, Gurses I, et al. Do sodium channel blockers have neuroprotective effect after onset of ischemic insult?. Neurol Res 2007;29:317-23
53. Fritz E, Izaurieta P, Weiss A, et al. Mutant SOD1-expressing astrocytes release toxic factors that trigger motoneuron death by inducing hyperexcitability. J Neurophysiol 2013;109:2803-14
54. Dupuis L, Gonzalez de Aguilar JL, di Scala F, et al. Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis 2002;10:358-65
55. Jokic N, Gonzalez de Aguilar JL, Pradat PF, et al. Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann Neurol 2005;57:553-6
56. Jokic N, Gonzalez de Aguilar JL, Dimou L, et al. The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Rep 2006;7:1162-7
57. Meininger V, Pradat P-F, Corse A, et al. Safety, pharmacokinetic, and functional effects of the nogo-A monoclonal antibody in amyotrophic lateral sclerosis: A randomized, first-in-human clinical trial. PLoS One 2014;9:e97803
58. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-9
59. Cohen J, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
60. Kano O, Beers D, Henkel J, Appel S. Peripheral nerve inflammation in ALS mice: Cause or consequence. Neurology 2012;78:833-5
61. Gowing G, Lalancette-Hebert M, Audet JN, et al. Macrophage colony stimulating factor (M-CSF) exacerbates ALS disease in a mouse model through altered responses of microglia expressing mutant superoxide dismutase. Exp Neurol 2009;220:267-75
62. Butovsky O, Siddiqui S, Gabriely G, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest 2012;122:3063-87
63. Speiser Z, Mayk A, Eliash S, Cohen S. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm 1999;106:593-606
64. Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol 1999;366:127-35
65. Stefanova N, Poewe W, Wenning G. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol 2008;210:421-7
66. Waibel S, Reuter A, Malessa S, et al. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol 2004;251:1080-4
67. Olanow C, Rascol O. The delayed-start study in Parkinson disease: Cant satisfy everyone. Neurology 2010;74:1149-50
68. Ahlskog J, Uitti R. Rasagiline, Parkinson neuroprotection, and delayed-start trials: Still no satisfaction?. Neurology 2010;74:1143-8
69. Nefussy B AI, Drory VE. Treatment with rasagiline in patients with amyotrophic lateral sclerosis. Ann Neurol 2007;62:S60-0
70. Swerdlow R, Parks J, Pattee G, Parker W. Role of mitochondria in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:185-90
71. Siklos L, Engelhardt J, Harati Y, et al. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Ann Neurol 1996;39:203-16
72. Bowling A, Schulz J, Brown R, Beal M. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1993;61:2322-5
73. Fujita K, Yamauchi M, Shibayama K, et al. Decreased cytochrome c oxidase activity but unchanged superoxide dismutase and glutathione peroxidase activities in the spinal cords of patients with amyotrophic lateral sclerosis. J Neurosci Res 1996;45:276-81
74. Wang YX, Moore D, Katz J, et al. A multicenter screening trial of the safety and efficacy of rasagiline in people with ALS. Neurology 2013;80:S36.006
75. Macchi YW Z, Moore D, et al. Possible mitochondrial target engagement in an open-label trial of rasagiline for ALS. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:230
76. Traub R, Mitsumoto H, Rowland L. Research advances in amyotrophic lateral sclerosis, 2009 to 2010. Curr Neurol Neurosci Rep 2011;11:67-77
77. Gordon P. Amyotrophic lateral sclerosis: An update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis 2013;4:295-310
78. Xu L, Yan J, Chen D, et al. Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation 2006;82:865-75
79. Xu L, Ryugo D, Pongstaporn T, et al. Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: Differentiation and structural integration into the segmental motor circuitry. J Comp Neurol 2009;514:297-309
80. Xu L, Shen P, Hazel T, et al. Dual transplantation of human neural stem cells into cervical and lumbar cord ameliorates motor neuron disease in SOD1 transgenic rats. Neurosci Lett 2011;494:222-6
81. Xu L, Mahairaki V, Koliatsos V. Host induction by transplanted neural stem cells in the spinal cord: Further evidence for an adult spinal cord neurogenic niche. Regen Med 2012;7:785-97
82. Glass J, Boulis N, Johe K, et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: Results of a phase I trial in 12 patients. Stem Cells 2012;30:1144-51
83. Feldman E, Boulis N, Hur J, et al. Intraspinal neural stem cell injections in ALS subjects: Phase I trial outcomes. Ann Neurol 2014;75:363-73
84. Boulis N, Federici T, Glass J, et al. Translational stem cell therapy for amyotrophic lateral sclerosis. Nat Rev Neurol 2011;8:172-6
85. Lunn J, Sakowski S, Federici T, et al. Stem cell technology for the study and treatment of motor neuron diseases. Regen Med 2011;6:201-13
86. Lunn J, Sakowski S, Feldman E. Stem cell therapies for amyotrophic lateral sclerosis: Recent advances and prospects for the future. Stem Cells 2014;32:1099-109
87. Knippenberg S, Thau N, Dengler R, et al. Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS. PLoS One 2012;7:e36857
88. Minguell J, Allers C, Lasala G. Mesenchymal stem cells and the treatment of conditions and diseases: The less glittering side of a conspicuous stem cell for basic research. Stem Cells Dev 2013;22:193-203
89. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010;67:1187-94
90. Gordon P, Moore D, Miller R, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial. Lancet Neurol 2007;6:1045-53
91. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 1999;52:1427-33
92. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 1996;46:1244-9
93. Sorenson E, Windbank A, Mandrekar J, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008;71:1770-5
94. Ochs G, Penn R, York M, et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:201-6
95. Shefner J, Watson M, Simionescu L, et al. Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology 2011;77:235-41
96. Shefner J, Cudkowicz M, Zhang H, Northeast ALSC. The use of statistical MUNE in a multicenter clinical trial. Muscle Nerve 2004;30:463-9
97. Sacca F, Quarantelli M, Rinaldi C, et al. A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: Clinical, neuroimaging, and hormonal results. J Neurol 2012;259:132-8
98. Duning T, Schiffbauer H, Warnecke T, et al. G-CSF prevents the progression of structural disintegration of white matter tracts in amyotrophic lateral sclerosis: A pilot trial. PLoS One 2011;6:e17770
99. Rutkove S, Caress J, Cartwright M, et al. Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler 2012;13:439-45